Announcement on Voluntary Disclosure of Approval of ALK Inhibitor Conteltinib Granules (Shouyaoze®) for Marketing by the National Medical Products Administration

About this update from Shouyao Holdings Beijing Co. Ltd. Class A

Announcement on Voluntary Disclosure of Approval of ALK Inhibitor Conteltinib Granules (Shouyaoze®) for Marketing by the National Medical Products Administration The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Shouyao Holdings Beijing Co. Ltd. Class A